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Background. Angiogenesis has been recently described as a novel component of inflammatory bowel disease pathogenesis.
The level of vascular endothelial growth factor (VEGF) has been found increased in Crohn’s disease and ulcerative colitis
mucosa. To question whether a pro-inflammatory Escherichia coli could regulate the expression of VEGF in human intestinal
epithelial cells, we examine the response of cultured human colonic T84 cells to infection by E. coli strain C1845 that belongs to
the typical Afa/Dr diffusely adhering E. coli family (Afa/Dr DAEC). Methodology. VEGF mRNA expression was examined by
Northern blotting and q-PCR. VEGF protein levels were assayed by ELISA and its bioactivity was analysed in endothelial cells.
The bacterial factor involved in VEGF induction was identified using recombinant E. coli expressing Dr adhesin, purified Dr
adhesin and lipopolysaccharide. The signaling pathway activated for the up-regulation of VEGF was identified using a blocking
monoclonal anti-DAF antibody, Western blot analysis and specific pharmacological inhibitors. Principal Findings. C1845
bacteria induce the production of VEGF protein which is bioactive. VEGF is induced by adhering C1845 in both a time- and
bacteria concentration-dependent manner. This phenomenon is not cell line dependent since we reproduced this observation
in intestinal LS174, Caco2/TC7 and INT407 cells. Up-regulation of VEGF production requires: (1) the interaction of the bacterial
F1845 adhesin with the brush border-associated decay accelerating factor (DAF, CD55) acting as a bacterial receptor, and (2)
the activation of a Src protein kinase upstream of the activation of the Erk and Akt signaling pathways. Conclusions. Results
demonstrate that a Afa/Dr DAEC strain induces an adhesin-dependent activation of DAF signaling that leads to the up-
regulation of bioactive VEGF in cultured human intestinal cells. Thus, these results suggest a link between an entero-adherent,
pro-inflammatory E. coli strain and angiogenesis which appeared recently as a novel component of IBD pathogenesis.
Citation: Cane G, Moal VL-L, Page `s G, Servin AL, Hofman P, et al (2007) Up-Regulation of Intestinal Vascular Endothelial Growth Factor by Afa/Dr
Diffusely Adhering Escherichia coli. PLoS ONE 2(12): e1359. doi:10.1371/journal.pone.0001359
INTRODUCTION
The two major forms of inflammatory bowel disease (IBD), Crohn’s
disease (CD) and ulcerative colitis (UC) have been defined on the
basis of clinical, endoscopic and radiological criteria. The molecular
pathogenesis of CD and UC appeared complex involving genetic
susceptibility, modified innate or adaptative immune responses,
multifactorial alterations in intestinal barrier function, mucosal
homeostasisandtheintestinal microflora [1–4]. Indeed, accumulative
evidence suggests a role of resident intestinal microbiota or
enterovirulent E. coli strains in initiation and pathogenesis of IBD.
Particularly, studies highlighted a correlation between an increase in
the number of biofilm-forming mucosal bacteria and pathogenesis of
CD [5–7]. Identification of bacterial strains involved in etiology of
IBD is not an easy task, however Tiveljung and co-workers have
reported the presence of E. coli-, Helicobacter spp.-, Mycobacterium
paratuberculosis-a n dL. monocytogenes-like 16S rDNA sequences in
biopsies from the terminal ileum of CD patients [8]. E. coli have also
beenfoundabnormallypredominantinearlyandchronicileallesions
of CD patients [9]. Interestingly, healthy and ulcerated mucosa are
colonized by E. coli strains having the same ribotype profile, which
indicates uniform colonization regardless of the inflammatory state of
the mucosa [10]. Finally, an adherent-invasive E. coli (AIEC) strain
has been isolated from neoterminal ileum of CD patients [11–13].
Their virulence properties designate AIEC as a possible pathogen
potentially able to induce persistent intestinal inflammation, by
crossing and breaching the intestinal barrier, moving to deep tissues,
promoting granulomas, continuously activating macrophages and
producing inflammatory responses [14–18]. However, AIEC do not
represent a specific pathogen exclusively found in CD because their
presence was also observed in colonic control specimens.
Morphological, phenotypic and functional evidence of potent
angiogenic activity in Crohn’s disease (CD) and ulcerative colitis
(UC) mucosa has been recently reported by Danese and co-workers
[19]. In particular, an increase in microvessel density, associated to
the presence of bioactive vascular endothelial growth factor (VEGF),
wasobservedininflammatoryboweldisease(IBD).VEGFisnotonly
the most potent angiogenic factor but has also been described as a
mediator of tumor-associated immunodeficiency through inhibition
of T-cell development [20]. Angiogenesis involves the recruitment
and proliferation of endothelial cells from pre-existing vessels or
circulating endothelial progenitor cells originating from the bone
marrow [21]. The pleiotropic factor VEGF is secreted by tumor and
stromal cells and regulates endothelial cell survival, proliferation,
migration but also, allows the assembly of endothelial cells into
capillary like structures (for reviews see [22,23]).
In this study, we sought to determine if and how an entero-
adherent pro-inflammatory E. coli could regulate the expression of
Academic Editor: Mikhail Blagosklonny, Ordway Research Institute, United States
of America
Received October 31, 2007; Accepted November 25, 2007; Published December
26, 2007
Copyright:  2007 Cane et al. This is an open-access article distributed under
the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the
original author and source are credited.
Funding: This work was supported by the ‘‘Centre National de la Recherche
Scientifique’’ (CNRS), the Institut National de la Sante ´ et de la Recherche Me ´dicale
(Inserm), the ‘‘Association pour la Recherche sur le Cancer (ARC)’’, and the
Universities of Nice Sophia Antipolis’’ (UMR6543) and Paris-Sud 11 (UMR756).
Competing Interests: The authors have declared that no competing interests
exist.
* To whom correspondence should be addressed. E-mail: vouret@unice.fr
PLoS ONE | www.plosone.org 1 December 2007 | Issue 12 | e1359VEGF in human intestinal epithelial cells. To do this, we focused
our attention on Afa/Dr diffusely adhering E. coli (Afa/Dr DAEC)
strains which belong to class six of the enterovirulent E. coli strains
[24]. These strains of E. coli express a family of adhesins that are
encoded by a family of operons consisting of at least five genes
including the afa, dra and daa genes (for review see [25]). A recent
epidemiological study demonstrates that bacteria expressing Afa
adhesins adhere to the mucosa of patients with IBD [26]. Through
Afa/Dr adhesins, these bacteria interact with membrane-bound
receptors including the decay-accelerating factor (DAF/CD55)
(Afa/Dr DAECDAF) and members of the human carcinoembryo-
nic-antigen-related cell-adhesion molecules (CEACAMs) family
(Afa/Dr DAECCEACAMs). It was previously demonstrated that the
Afa/Dr DAEC strain C1845 [27] is an entero-adherent, pro-
inflammatory E. coli that activates the extracellular regulated
kinase/mitogen-activated protein kinases (Erk/MAP kinase)
signaling pathway in human intestinal T84 cell monolayers
promoting interleukin 8 (IL8) secretion and the transepithelial
migration of polymorphonuclear neutrophils (PMNs), a feature of
chronic inflammation [28]. In turn, the activated PMNs promote
the production of tumor necrosis factor-a (TNFa) and interleukin-
1b (IL1-b) that lead to the over-expression of DAF at the apical
and basolateral domains of T84 cells [29]. Interestingly enough,
DAF is upregulated in UC [30–32]. Moreover, in cultured Caco-2
cells specific interaction between bacterial adhesin AfaE-III and
DAF leads to increased expression of MHC class 1 related molecule
(MICA) suggesting that this host-bacteria interaction pathway could
play a role in the pathogenesis of IBD since increased-MICA
expression has been found at the surface of colonic epithelial cells in
CD-affected patients [33]. Very recently, E. coli strain of the B2+D
phylogenetic groups of Enterobacteriaceae have been found more likely
to be associated with tissues from patients with UC and CD than
from controls [34]. This phylogenetic group express a functional
serine protease autotransporter (SPATE) and adherence factors.
Interestingly, Afa/Dr DAEC express SPATE, also named Sat, and
Sat isinvolved inthe Afa/DrDAEC-induced breach of the intestinal
epithelial barrier [35].
In this study we show that Afa/Dr DAEC C1845 bacteria,
following the recognition of DAF by the F1845 adhesin, activate
Akt- and the extracellular signal-regulated kinase (Erk)-signaling
pathways through a Src protein kinase-dependent mechanism, and
induce a gene transcription program leading to the up-regulation
of VEGF expression.
RESULTS
Wild-type C1845 bacteria increase the production of
VEGF in cultured human intestinal T84 cells
We performed experiments on the human colonic carcinoma T84
cell line that maintains the morphological and functional
characteristics of epithelial tissues [36] and that has been widely
used in the fields of inflammation and infection [37]. Bacterial
infection, with a multiplicity of infection of 20 bacteria per
epithelial cells, was performed at 37uC on polarized, starved T84
epithelial cells. Careful microscopic observation of cells after
infection with control or wild-type C1845 bacteria did not reveal
any cell toxicity (data not shown). We tested by q-PCR the
expression of genes encoding for VEGF and for the pro-
inflammatory cytokine IL8, which is used here as a control of
the wild type C1845–induced pro-inflammatory responses. Results
show in table 1 that VEGF and IL8 genes are up-regulated by 3.6
and 1.7-fold, respectively, in wild-type C1845-infected T84 cells as
compared with non-infected cells. Observation that the genes
coding for Transforming growth factor Receptor 2 (TGFb R2),
Epithelial growth factor receptor 1 (EGF R1) and placental growth
factor (plGF) are not modulated indicate that the up-regulation of
VEGF and IL8 genes do not result of a general up-regulation
program in wild-type C1845-infected T84 cells. This result
highlights the capacity of wild-type C1845 bacteria to specifically
regulate the expression of genes coding for a major angiogenic
factor and a pro-inflammatory cytokine.
Northern blot analysis of total RNA using a specific probe for
the VEGF gene shows a very low level of VEGF mRNA
expression in control, non-infected T84 cells while a time and
dose-dependent increase in VEGF mRNA expression was
observed in T84 infected cells (Figure 1A, upper panel). The
transcript of 4 kb is preferentially expressed, however the
expression of the three other spliced variants, ranging from 1.5
to 4.0 kb, is revealed with a longer exposure of the autoradiogram
(data not shown). VEGF mRNA expression in non-infected and
wild-type C1845-infected T84 cells was also quantified by q-PCR
(Figure 1A, lower panel). The maximum increase in VEGF
mRNA expression (3.6-fold increase) was achieved when cells were
infected with 5610
7 CFU/ml of wild-type C1845 bacteria for four
hours. This increase in VEGF mRNA expression in response to
wild-type C1845 bacteria is neither cell line-dependent, since we
observed the same effect in the human LS174 colon cell line and
the fully-differentiated enterocyte-like Caco-2/TC7 cells nor
transformation-dependent since bacteria increase the expression
of VEGF in INT407, a non-transformed cell line (Figure 1B).
In order to examine the effect of C1845 bacteria on VEGF
production, we assayed the levels of secreted VEGF by an ELISA,
in culture medium of non-infected and wild-type C1845-infected
T84 cells. As shown in Figure 1C, C1845-infected cell supernatant
contains 3.4-fold more VEGF protein than the control supernatant
of non-infected cells.
To further demonstrate that the VEGF present in culture
medium of wild-type C1845-infected T84 cells, was biologically
functional, we used three different tests in Human Umbilical Vein
Endothelial Cell (HUVEC): the determination of
3H-methyl
thymidine incorporation into DNA, an index of cell proliferation,
activation of extracellular regulated kinase (Erk) and the formation
of tube like structures in matrigel [38]. As shown in Figure 2A,
VEGF contained in the culture medium of wild type C1845-
infected T84 cells (bars 4 and 5) increases thymidine incorporation
into HUVEC DNA to the same extend than recombinant human
VEGF (bar 2). By the same way, conditioned medium of wild type
C1845-infected T84 cells triggers the phosphorylation of Erk1/2
Table 1. Wild-type C1845-induced gene expression
......................................................................
Genes (assay ID) Fold induction
VEGF (Hs00173626_m1) 3.6060.45 (n=4)*
IL8 (Hs00174103_m1) 1.7060.16 (n=3)*
PlGF (Hs00182176_m1) 1.0060.16 (n=3)*
TGFb R2 (Hs00234253_m1) 0.7860.21 (n=2)
EGF R1 (Hs00193306_m1) 0.70 (n=2)
Cells were infected for four hours with Afa/Dr DAEC wild-type strain C1845 and
total RNA extracted. Selected gene expression was assayed by q-PCR. The
oligonucleotides used in this study were designed by Applied Biosystems, the
manufacturer’s references are given in brackets. Abbreviations are as follows:
VEGF: Vascular Endothelial Growth Factor, IL8: interleukin 8, PlGF: Placental
growth factor, TGFb R2: Transforming growth factor Receptor 2, EGF R1:
Epithelial growth factor Receptor 1. Results (means6SD) are representative of
independent experiments (where n represents the number of experiments). *,
p,0.001 versus non infected cells.
doi:10.1371/journal.pone.0001359.t001
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PLoS ONE | www.plosone.org 2 December 2007 | Issue 12 | e1359in HUVEC (Figure 2B, lanes 3 and 4) as does recombinant VEGF
(lane 2). And finally, only the medium conditioned by C1845
bacteria is able to induce the formation of tube like structures in
matrigel (Figure 2C). We conclude from these experiments that
VEGF produced by intestinal cells challenged with wild type
C1845 bacteria is fully active.
VEGF production induced by wild-type C1845
bacteria depends on DAF activation
We examined whether the interaction of wild-type C1845 bacteria
with its membrane-bound receptor, the DAF [39], triggers the up-
regulation of VEGF mRNA expression. T84 cells were pre-treated
for 1 hour with the IH4 blocking monoclonal antibody and then
infected for 2 hours with wild-type C1845 bacteria. As shown in
Figure 3A, the levels of VEGF mRNA in non-infected or non-
infected and IH4-treated cells are not significantly different,
indicating that the antibody by itself does not interfere with VEGF
mRNA expression. In the wild-type C1845-infected cells, the 1.8-
fold increase in the level of the VEGF mRNA is fully blocked
when cells are pre-treated with the IH4 antibody. This result
clearly demonstrates that activation via DAF is a pre-requisite for
signaling leading to VEGF production.
An increase in the VEGF mRNA level could be due to a
transcriptional and/or a post-transcriptional effect. We used the
transcriptional inhibitor 5, 6-dichloro-1-beta-d-ribofuranosylben-
zimidazole (DRB), which reversibly inhibits RNA polymerase II to
test whether the increase in VEGF mRNA is linked to a
Figure 1. C1845 bacteria increase VEGF expression in cultured intestinal epithelial cells. In A, increase in VEGF mRNA expression. Confluent serum-
starved T84 cells (5610
6 cells/well) were infected with wild-type C1845 bacteria and total RNA was prepared as indicated in the Materials and Methods
section. Results for non-infected (NI) or cells infected with 5610
7 CFU/ml C1845 bacteria for the indicated time are shown on the left panel. The dose
responseeffectispresented onthe right. Cells wereinfectedfor four hours withthe indicatednumber ofbacteria. ResultsofNorthern blots are presented
in the upper part of the Figure and q-PCR shown in the lower part. These results are representative of three independent experiments. In B, confluent
serum-starved LS174, Caco-2/TC7 or INT407 cells were infected with 5610
7 CFU/ml wild-type C1845 bacteria for four hours. VEGF mRNA expression was
assayed by q-PCR. The signal corresponding to VEGF and 36B4 transcripts was quantified using a phosphoImager. Under each condition the signal was
normalizedtothe36B4probe.Resultsareexpressedasarbitrary units correspondingtothe foldstimulationoftreatedversusnon-treatedconditions. In C,
increaseinthe VEGF protein intheculturemediumofwild-typeC1845-infectedT84cells.Cells wereinfectedwith5610
7 CFU/mlwild-type C1845bacteria
for four hours and the supernatant were collected as indicated in the Materials and Methods section. The VEGF protein level was then quantified using an
ELISA. Quantification of the results from two independent experiments (means6SD) is shown. *, p,0,01
doi:10.1371/journal.pone.0001359.g001
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PLoS ONE | www.plosone.org 3 December 2007 | Issue 12 | e1359transcriptional mechanism. As shown in Figure 3B, when the non-
infected T84 cells are pre-treated with DRB, the basal level of
VEGF mRNA decreased by two-fold. This indicates that the
VEGF gene is transcribed at a basal level. Treatment of the wild
type C1845-infected cells with DRB totally abolished the increase
in VEGF mRNA expression. Yet, we conclude that the induction
of VEGF mRNA by wild type C1845 bacteria is largely dependant
on transcriptional regulation.
Figure 2. Proliferative response, Erk activation and tube like structure formation in HUVEC in the presence of culture medium of wild-type
C1845-infected T84 cells.
3H-thymidine incorporation into DNA and Erk activation were essayed in HUVEC incubated with the following. In A,
3H-
thymidine incorporation into DNA. Control (1), VEGF at 10 ng/ml (2), culture medium of non-infected T84 cells (3), culture medium of wild-type
C1845-infected T84 cells (16) (4), culture medium of wild-type C1845-infected T84 cells (0.56) (5). In B, Western blot showing phospho-Erk1/2 and
total Erk1/2 visualized with respectively anti-phospho-Erk and anti-Erk antibodies. Control (1), VEGF at 10 ng/ml (23), culture medium of wild-type
C1845-infected T84 cells (16) (3), culture medium of wild-type C1845-infected T84 cells (0.56) (4). The results are representative of at least three
independent experiments. *, p,0,01. In C, Endothelial cells were seeded on matrigel and incubated with growing medium (control) alone or
supplemented with T84 conditionned medium (CM), C1845–condition medium (C1845) or VEGF. Images show that only C1845-conditionned
medium (C1845) and VEGF allow the alignment of endothelial cells in tube like structure.
doi:10.1371/journal.pone.0001359.g002
Figure 3. Increase in VEGF mRNA by wild-type C1845 bacteria requires binding to brush border-associated DAF. In A, binding to DAF is necessary
for the C1845-induced increase in VEGF mRNA expression. Confluent serum-starved T84 cells infected were with wild-type C1845 at 5610
7 CFU/ml,
which represents a multiplicity of infection of 20 bacteria per epithelial cell, for two hours. When indicated, cells were treated for 30 minutes priort o
infection with the anti-DAF blocking IH4 monoclonal antibody. VEGF mRNA expression was assayed by q-PCR. *, p=0,03 (n=7). In B, wild-type
C1845-induced VEGF mRNA increase is blocked by transcription inhibitor. Confluent serum-starved T84 cells were pre-treated for 30 minutes with
25 mg/ml of the reversible transcription inhibitor, 5,6-dichloro-1-beta-D-ribobenzimidazole (DRB). Cells were then infected with 5610
7 CFU/ml wild-
type C1845 for four hours and total RNA prepared. The relative quantity of VEGF mRNA was measured by q-PCR. Quantification of the results from
three independent experiments (means6SD) is shown. *, p,0,01.
doi:10.1371/journal.pone.0001359.g003
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PLoS ONE | www.plosone.org 4 December 2007 | Issue 12 | e1359A member of the Src kinase family, Akt and Erk are
involved in wild type C1845-induced VEGF
production
Having demonstrated that DAF recognition is necessary to
transmit signals from the membrane to the nucleus, we further
characterized which signaling pathways are involved in wild type
C1845-induced VEGF production. Given that in most cell lines
the Akt and Erk pathways are largely involved in VEGF
production [40], we tested whether wild-type C1845 bacteria
activate these kinases. T84 cells were infected with increasing
doses of wild-type C1845 bacteria for 2 hours and cell proteins
were extracted. The Akt or Erk activities were assayed by Western
blotting with antibodies against the active phospho-proteins. Both
Akt (Figure 4A) and Erk (Figure 4B) were activated following wild-
type C1845 infection. The maximum of both Akt and Erk
activation was observed at a concentration of 10
8 CFU/ml of wild-
type C1845 bacteria, which represents a multiplicity of infection of
50 bacteria per epithelial cell, with respectively 9.7 and 18.2-fold
stimulation. Interestingly, the activation of both kinases is inhibited
when the wild-type C1845-infected cells were pre-treated with the
DAF blocking monoclonal antibody IH4.
In INT 407 epithelial cells, it was observed previously that wild-
type C1845 bacteria promote a protein kinase C (PKC) activation
[41]. We used GF 109203X (GFX), a selective cell-permeable
inhibitor of the PKCa, bI, bII, c, d and e isoforms, to determine
whether PKC could regulate the wild-type C1845-induced Erk
and/or Akt pathways. Pre-treatment of T84 cells with GFX did
not significantly modify either the basal level or the C1845-
stimulated level of Akt (Figure 5A) or Erk (Figure 5B). Thus, in
response to DAF recognition PKC is not involved in the regulation
of Akt and Erk in C1845-infected T84 epithelial cells. As expected,
we found that Akt- and Erk-activation were fully blocked by the
PI3K inhibitor (LY294002) and the MEK inhibitor (U0126),
respectively (Figure 5A and B).
We sought to determine the molecular intermediates acting
between the DAF receptor and these two signaling pathways. It
has been shown that the GPI-anchored DAF has signal
Figure 4. Wild-type C1845 bacteria induce Akt and Erk signaling pathways in T84 epithelial cells. Confluent serum-starved T84 cells were non-
infected (NI) or infected with increasing concentrations of wild-type C1845 bacteria, for two hours. When indicated, cells were pre-treated with an
anti-DAF blocking IH4 monoclonal antibody prior to or in the absence of infection. In A, phospho-Akt and total Akt were assayed by Western blotting
using respectively anti-phospho-Akt and anti-Akt antibodies. In B, phospho-Erk1/2 and total Erk1/2 were visualized with respectively anti-phospho-
Erk and anti-Erk antibodies. These results are representative of at least three independent experiments.
doi:10.1371/journal.pone.0001359.g004
Figure 5. A Src protein is involved in wild-type C1845-induced Akt and Erk activation. Confluent serum-starved T84 cells were pre-treated with
15 mM LY294002 (LY), 10 mM U0126 (U0), 5 mM GF109203X (GFX) or 5 mM PP2 for 30 minutes prior to infection or no infection with wild-type C1845
bacteria at 5610
7 CFU/ml for two hours. Cells were lyzed in SDS sample buffer and phospho-Akt and total Akt (in A) and phospho-Erk and total Erk1/2
(in B) assayed by Western blotting as described in Figure 5. These results are representative of at least three independent experiments.
doi:10.1371/journal.pone.0001359.g005
DAEC and VEGF Production
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to associate with p56lck and p59fyn in cells [42], we tested the
hypothesis that a Src kinase could be implicated in wild-type
C1845-induced signaling pathways. T84 cells were pre-treated
with the PP2 inhibitor of Src kinase and the Akt or Erk activity was
assayed by Western blotting. As shown in Figure 5A and B, in the
presence of PP2 both the wild-type C1845-induced increase of Akt
and Erk activities were inhibited in infected cells as compared with
the non-infected cells. This demonstrates that a Src protein kinase
is activated downstream of DAF recognition by wild-type C1845
bacteria and is necessary to transduce the signal to Akt and Erk.
Using this pharmacological approach, we then verified whether
these pathways are required for VEGF mRNA expression in
response to wild type C1845 bacteria. Prior to C1845 infection,
T84 cells were pre-treated with the different inhibitors used above.
Total RNA was extracted and the level of the VEGF transcripts
was assayed by q-PCR. As shown in Figure 6, when the C1845-
infected cells are pre-treated with the Src inhibitor, PP2, the
increase in VEGF mRNA was inhibited. Interestingly, we
observed the same result when the C1845-infected cells were
treated with the MEK inhibitor, U0126 whereas the PI3K
inhibitor partially blocked the production of the VEGF transcript
in wild type C1845-infected cells. This partial inhibition suggests
that VEGF transcription is regulated by at least two distinct
signalling pathways in which Erk activation is a pre requisite for
PI3K/Akt effect on VEGF promoter. We conclude that a Src-
dependant Erk pathways is required to increase VEGF mRNA
expression in response to C1845 bacteria.
F1845 adhesin is the bacterial factor involved in
VEGF up-regulation
We further conduct experiments in order to identify the bacterial
factor that was responsible for the up-regulation of VEGF in
intestinal cells. DAF has been demonstrated to be part of the
lipopolysaccharide (LPS)-induced receptor complex [43]. Despite
the fact that T84 cells have been described previously to be
completely unresponsive to LPS [44], we wanted to clarify this
point. We purified LPS from the non-pathogenic strain AAEC185
and from the wild-type strain C1845 and examined whether these
purified LPS could induce signaling pathways on T84 cells. As
shown in Figure 7A, up to 5 mg/ml of LPS purified from wild-type
C1845 or non-pathogenic AAEC185 bacteria were not able to
induce an increase in Erk activity, or VEGF production (data not
shown), whereas wild-type C1845 bacteria efficiently increase the
level of phosphorylated forms of Erk (Figure 7A).
We further checked that F1845 adhesin is involved in the
induction of Erk signaling pathway. T84 cells were infected with
non-pathogenic strain AAEC185 or recombinant E. coli AAEC185-
F1845 strain expressing the pSSS1 plasmid encoding the F1845
adhesin, and Erk activity was assayed by Western blotting using an
anti phospho-Erk antibody. As shown in Figure 7B, only the
recombinant AAEC185-F1845 strain, increases the phosphorylation
of Erk. We also performed the same experiment with the F1845
adhesin purified from wild-type strain C1845 (Figure 7C). As shown
in Figure 7D, two micrograms of the purified F1845 adhesin were
able to stimulate Erk activity inT84 cells.
We further controlled whether the F1845 adhesin increases the
VEGF mRNA expression in T84 cells. For this purpose, we used
the non-pathogenic E. coli AAEC185 and the recombinant
AAEC1845-F1845 strain. When the cells were infected for four
hours with the recombinant AAEC1845-F1845 strain, we
observed a 3.2-fold increase in VEGF mRNA expression
(Figure 7E). In contrast, when the cells were infected for the same
time with the control AAEC185 strain no increase in the level of
VEGF mRNA expression was observed. These results indicate
that the F1845 adhesin expressed by recombinant strain E. coli
AAEC185-F1845 induces the up-regulation of VEGF expression
in T84 human intestinal epithelial cells.
DISCUSSION
For many years it was suspected that increased VEGF expression
and angiogenesis were associated with IBD [45–50]. In particular,
during IBD the density of the microvasculature of the colon is
increased allowing an increase in leukocyte recruitment and
subsequent tissue damage. This observation leads to the concept
that angiogenesis may play a pathological role in IBD [51]. The
ultimate demonstration that a link between IBD and angiogenesis
exits arise from two recent observations: vascular remodeling and
functionally active angiogenesisare associated with IBD [52] and the
angiogenic blockade, using the anti-angiogenic peptide ATN-61, has
decreased angiogenesis in two colitis-associated mice models [19].
Interestingly, although serum VEGF levels and angiogenesis are
increased in IBD and correlate with disease activity, they do not
appear genetically determined [53], suggesting that external
factors are involved in VEGF up-regulation. Examining the
cellular sources of VEGF in IBD mucosa, it was found that lamina
propria mononuclear cells stimulated or not by LPS and human
intestinal fibroblasts stimulated with TNF-a produce VEGF,
whereas unstimulated or TNF-a-stimulated intestinal microvascu-
lar endothelial cells produce negligible amount of VEGF [19].
Here, we demonstrate that the human intestinal epithelial cells are
a novel source of VEGF when challenged by the entero-adherent,
pro-inflammatory Afa/Dr DAEC C1845 strain.
We identified in T84 human intestinal cells the mechanism by
which VEGF is up-regulated in response to wild type C1845
strain. The process of induction implies the recognition of a
membrane-bound receptor DAF by the bacterial F1845 adhesin.
DAF, the receptor for Afa/DrDAF adhesions [39,54], is associated
via its GPI-anchor with lipid rafts, sphingolipids and signaling
proteins [55]. In intestinal and non-intestinal epithelial cells, DAF
is clustered around adhering Afa/Dr bacteria [56,57]. As for the
Figure 6. Wild-type C1845-induced VEGF expression is dependant on
Src and Erk proteins. Confluent serum-starved T84 cells were pre-
treated with 5 mM PP2, 10 mM U0126 or 15 mM LY294002 for
30 minutes. Cells were then infected with wild-type C1845 bacteria at
5610
7 CFU/ml for four hours. Total RNA was prepared and the relative
quantity of VEGF mRNA was measured by q-PCR. Quantification of the
results from four independent experiments (means6SD.) is shown. *,
p,0.005 versus non infected cells.
doi:10.1371/journal.pone.0001359.g006
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that link DAF to signaling pathways are not yet fully characterized.
However, in T-cells, cross-linked-DAF becomes tyrosine phos-
phorylated and is associated with the p56
lck and p59
fyn protein
tyrosine kinases. Here, using a blocking mAb directed against DAF
and the PP2 compound, a large spectrum inhibitor of the Src
family protein tyrosine kinases, we demonstrate that the up-
regulation of VEGF was a DAF- and Src kinase-dependent
mechanism. Downstream the activated Src family kinase(s), we
identified the Erk and Akt signaling pathways as involved in the
C1845-induced up-regulation of VEGF. Angiogenesis a conse-
quence of increasing expression of VEGF through the activation of
Erk and PI3K/Akt pathways has been previously described in
relation with progression of tumors but not in IBD. For examples,
PI3K/Akt and Erk signaling pathways are involved in bcl-2-
induced VEGF expression in melanoma cells [58]. VEGF up-
regulation via both PI3K and Erk pathways occurs in fibroblasts
[59,60]. Up-regulation of VEGF by Gram negative [61–67] and
Gram positive [68–70] bacteria has been previously reported.
Gastrointestinal pathogens including Helicobacter pylori [71–73] and
Listeria monocytogenes [74] increased the expression of VEGF
mRNAs through a Erk-mediated pathway, as we found here for
the wild-type Afa/Dr DAEC strain C1845. It was noticed that H.
pylori [75], as Afa/Dr DAEC [39,54], use DAF as a receptor.
In the light of the recent findings that angiogenesis might
contribute to the initiation and perpetuation of IBD, our results
showing that an entero-adherent, pro-inflammatory bacteria has
the capacity to induce the up-regulation of the most potent
angiogenic factor VEGF, are of major interest. It was recently
proposed that Afa/Dr DAEC is a ‘‘silent pathogen’’ that can
emerge from the human intestinal microbiota (for review see [25]).
Whether the adhesin-dependent signaling pro-inflammatory
events induced by Afa/Dr DAEC in different cultured human
intestinal cell lines observed here and previously [28,29,33] are
Figure 7. F1845 adhesin but not LPS, activates Erk and increases VEGF expression. In A, confluent serum-starved T84 cells were non infected (NI),
infected with 5610
7 CFU/ml wild-type C1845 bacteria, or treated for 2 hours with indicated concentration of LPS purified from non-pathogenic
AAEC185 or C1845 strains. Phospho-Erk1/2 and total Erk1 were visualized by Western Blotting with respectively anti-phospho-Erk and anti-Erk1
antibodies. This experiment is representative of two independent experiments. In B, confluent serum-starved T84 cells were non-infected (NI),
infected with increasing concentrations of AAEC185 or recombinant AAEC185-F1845 strains for 2 h. Phospho-Erk and total Erk-1 were assayed by
Western blotting using respectively anti-phospho-Erk and anti-Erk1 antibodies. In C, coomassie-stained polyacrylamide-SDS gel of fimbriae purified
from C1845 or AAEC185 bacteria. 1 mg of bovine serum albumine (BSA) are showed on the left of the gel. In D, confluent serum-starved T84 cells
were non treated (NT) or incubated 2 h in the presence of extracts of C1845 bacteria (containing 2 mg of purified F1845 adhesin) or AAEC185
bacteria. These result are representative of three independent experiments. In E, confluent serum-starved T84 cells (5610
6 cells/well) were infected
with AAEC185 bacteria or recombinant AAEC185-F1845 bacteria expressing the pSSS1 operon encoding the F1845 adhesin (5610
7 CFU/ml). Total
RNA were extracted and analysed by q-PCR. These results are representative of at least two independent experiments (means6SD).
doi:10.1371/journal.pone.0001359.g007
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determined. Formal demonstration requires further in vivo
experiments in appropriate humanized animal models since the
receptors for Afa/Dr DAEC, DAF [76] and human CEACAMs
(A. Servin, personal communication), are highly specific of human.
In addition, it remains to be determined whether other entero-
adherent E. coli strains and AIEC strains isolated from IBD
mucosa are able to up-regulate VEGF expression in intestinal cells.
MATERIALS AND METHODS
Reagents and antibodies
All reagents, unless specified, were from Sigma Chemicals (Saint
Quentin Fallavier, France). Tissue culture plastic ware was from
Nunc (Roskilde, Denmark). The Src family kinase inhibitor PP2
[4-amino-5-(4-chlorophenyl)-7(t-butyl)pyrazololol[3,4-d]-pyrimid-
ine] and the Protein Kinase C inhibitor GF109203X (bisindo-
lylmaleimide 1) were from Calbiochem. The MAP/Erk Kinase
(MEK) inhibitor U0126 was from Promega (Madison, WI, USA).
Anti Akt and anti-phospho Akt (pS473) polyclonal antibodies were
from Cell Signaling Technology (Beverly, MA). The rabbit
polyclonal anti-Erk antibody (E1B4) that preferentially recognizes
Erk2 was raised against a C-terminal Erk1 peptide. The anti-
phospho Erk antibody (clone MAPK-YT) and anti alpha-tubulin
antibody were from Sigma. The IH4 antibody was a gift from
D.M. Lublin (Washington University, St. Louis). This mAb is
specific of CCP3 domain of DAF [77]. It has previously been used
to map the Dr adhesin binding site to hDAF and its block the
complement regulatory function of DAF [57,78].
Bacterial strains
We used the wild type Afa/Dr DAEC C1845 [27], harboring
fimbrial F1845 adhesin, and as negative control the non-
pathogenic AAEC185 E. coli strain [79]. The bacteria were grown
overnight at 37uC on LB-agar plates and expanded in LB medium
at 30uC without shaking, in order to preserve the adhesins. After
PBS washing, bacteria were quantified by OD measurement (1.0
OD600=2 610
9 CFU/ml). Bacterial adherence on infected cells
was confirmed by microscopic observations.
LPS and adhesin purification
LPS preparations were prepared from the non-pathogenic
AAEC185 and wild-type C1845 strains, using the hot phenol-
water LPS extraction protocol as previously described by [80].
Bacterial endotoxin was quantified with the Limulus amebocyte
lysate (LAL) chromogenic assay, according to the manufacturer’s
instructions (LAL QCL-1000a, Cambrex).
Adhesins were purified as previously described in [27] and
quantified on a coomassie-stained SDS polyacrylamide gel.
Cell culture
The human colon carcinoma cell line T84 was supplied by the
ATCC (number CCL-248) 37]. The cells were cultured as a
monolayer for 6 to 7 days to confluency in DMEM:F12 medium
containing HEPES supplemented with 5% heat-inactivated fetal
calf serum (FCS) without antibiotics. The cells were maintained at
37uC in a 5% CO2-95% air atmosphere. Experiments were
performed on polarized cells (5 days post-confluence). Prior to
infection, cells were starved overnight in DMEM:F12 medium
containing HEPES without FCS. The Caco-2/TC7 clone,
established from the parental human enterocyte-like Caco-2 cell
line [81], was grown in DMEM supplemented with 20% heat-
inactivated fetal calf serum and 1% nonessential amino acids at
37uC in a 10% CO2-90% air atmosphere. For experiments, fully
differentiated cells were used. LS174 human colon adenocarcino-
ma cells (LS174T) and INT407 human embryonic intestinal cell
line isolated from the jejunum and ileum of a human embryo at
about 2 months of gestation were obtained from the ATCC, and
cultured in the recommended medium.
Human vascular endothelial cells were isolated from umbilical
cord veins by collagenase perfusion and maintained in culture as
previously described [82].
Preparation and analysis of RNA
Cells seeded in a 6-well plate were lysed in TRIzol (Invitrogen).
RNA was prepared according to the manufacturer’s protocol.
20 mg of RNA was used for Northern blot analysis and hybridized
with the VEGF probe (640 bp) corresponding to the coding region
of mouse VEGF (NCB accession number NM-009505). The 36B4
probe corresponds to the region comprised between bases 683 and
842 of the cDNA coding for the human acidic ribosomal
phosphoprotein P0 (NCB accession number M17885).
Real time quantitative amplification of RNA (q-PCR) was per-
formed on cDNA prepared according to the manufacturer’s protocol
(Omniscript RT kit, Quiagen). Q-PCR on indicated genes was
performed as follows. Two ml (5-fold dilution) of extracted cDNA was
used as template for PCR amplification in a 7300 Real Time PCR
system (Applied Biosystems). The relative expression of indicated
transcripts was quantified using the Taq man PCR Master Mix
(Eurogentec) and specific primers furnished by Applied Biosystemson
an ABI PRISM 7300 Sequence Detection System (Applied
Biosystems) using the 2
[2DDC(T)] method. According to this method,
the C(T) values for the expression of each transcript in each sample
wasnormalized to the C(T)valuesof the controlmRNA (36B4)inthe
same sample. The values of untreated cell samples were then set to
100% and the percent transcript expression was calculated. Each
experiment was done in duplicate. The results are representative of at
least three independent experiments. The significance of the results
was estimated by performing a Student’s t test.
ELISA of secreted VEGF
C1845-infected cell culture supernatants were collected, centri-
fuged at 10 000 rpm for 30 minutes and filtered on a 0.22 mM
filter to remove all remaining bacteria. Determination of the
VEGF concentration of all supernatants was carried out using an
ELISA kit Quantikine Human VEGF Immunoassay (R&D
Systems) following the manufacturer’s guidelines.
Western blotting
Serum-starved cells seeded in a 12-well plate were stimulated as
indicated and immediately lysed in SDS sample buffer. Protein
extracts were resolved by SDS-PAGE in a 10% gel and transferred
onto a PVDF membrane (Immobilon-P; Millipore). Membranes
were incubated overnight in the presence of the indicated
antibodies (previously diluted in milk), washed and then incubated
in the presence of a second anti-rabbit or anti-mouse horseradish
peroxidase-conjugated antibody. Bound antibody was revealed
using an ECL system (Millipore). Where indicated, immunoblots
were quantified using the GeneGnome chemiluminescent imaging
system (Syngene, Frederick, MD).
Mitogenesis assay
HUVEC were plated into 12-well plates and cultured as above
described. The cells were subjected or not to non-infected or wild-
type C1845-infected T84 culture medium for 12 h in serum-free
media.
3H-methyl thymidine (1 mCi) (AmershamBiosciences,Orsay,
DAEC and VEGF Production
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last 5 h of incubation. The reaction was stopped with ice-cold PBS.
The cells were washed with 5% perchloric acid, rinsed with PBS and
solubilized in Triton X-100 1%/NaOH 1%. The solubilized cells
were assayed for
3H using a TRI-CARB model 2300TR liquid
scintillation counter (PerlinElmer, Courtaboeuf, France).
Tube like structure formation
Capillary-like structure formation was analysed on a bed of
Matrigel (Beckton Diskinson) (200 ml Matrigel in 35 mm diameter
well). The gel was polymerized at 37uC and 5610
4 cells in
endothelial growth medium were seeded on the matrix. Morpho-
logical changes were microscopically monitored.
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